Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: TRI

Laser.ai helps in the pivotal study on prevention of the spread of COVID-19


HAMILTON, Ontario, June 5, 2020 /PRNewswire-PRWeb/ -- Evidence Prime Inc. announced today that its system for conducting Living Systematic Reviews (laser.ai) was successfully applied to verify screening decisions in the study published on June 1st in The Lancet https://doi.org/10.1016/S0140-6736(20)31142-9 by international COVID-19 Systematic Urgent Review Group Effort (SURGE) group. The paper provides the best available evidence based on 172 studies. It answers pressing questions, such as the optimal physical distance and universal use of face masks, and was commissioned by the World Health Organization.

"We see a lot of mixed guidance from public health authorities around the world on what preventive measures should be applied to reduce the spread of COVID-19. This study provides the long-awaited summary of the best available evidence on this topic", says Artur Nowak, CTO at Evidence Prime. "Given the unprecedented speed at which this work was done, our AI helped provide the researchers with peace of mind that no study was left behind".

Laser.ai allows the semi-automated synthesis of evidence, expediting the process and enabling living (always up-to-date) systematic reviews. The work is supported by the European Union under the European Regional Development Fund via the "LaSeR" project (a "Fast Track to Innovation" program by the Polish National Centre for Research and Development).

About Evidence Prime: Evidence Prime is a provider of highly specialized, AI-driven software solutions for evidence-based healthcare. It develops GRADEpro, used by more than 65,000 users worldwide for creating evidence synthesis, clinical practice guidelines, and decision aids. For more information, visit https://evidenceprime.com.

 

SOURCE Evidence Prime Inc.


These press releases may also interest you

at 08:25
Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first Canadian subject in its Phase 1 / 2 clinical trial (ABA-1, CLARA) of AURN001, a cell...

at 08:20
The "Highly Potent API Market - A Global and Regional Analysis: Focus on Type, Type of Synthesis, Therapeutic Area, Type of Manufacturing, End User, and Country - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's...

at 08:15
Keysight Technologies , today announced its intention to acquire the entire issued and to be issued share capital of Spirent Communications PLC (London Stock Exchange Symbol: SPT) ("Spirent") for a cash consideration of 199 pence per Spirent share...

at 08:15
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it will be attending the LSX World Congress (29-30 April) and presenting at Bio?quity Europe (12-14 May). The...

at 08:15
Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety...

at 08:15
Nuvation Bio Inc. , a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms....



News published on and distributed by: